Concepedia

Mary Louise Keohan

ML

66

Publications

6.3K

Citations

40

H-Index

1985

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Columbia University

Columbia University Irving Medical Center

Icahn School of Medicine at Mount Sinai

Mary Louise Keohan is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

1985–2024

66

Publications

66

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 569 citations · Full text

, , +13

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, William D. Tap, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2013 · 386 citations · Full text

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

Madhav V. Dhodapkar, Mario Sznol, Biwei Zhao et al. · Science Translational Medicine · 2014 · 351 citations

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

Suzanne George, Priscilla Merriam, Robert G. Maki et al. · Journal of Clinical Oncology · 2009 · 315 citations · Full text

, , +12

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib

Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan et al. · JAMA Oncology · 2016 · 310 citations · Full text

Rows per page

1–5 of 66